We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Burzynski Research Institute (PK) | USOTC:BZYR | OTCMarkets | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.05 | 0.05 | 0.05 | 0.00 | 00:00:00 |
From Jan 2020 to Jan 2025
HOUSTON, March 26, 2015 /PRNewswire/ -- The Burzynski Research Institute, Inc. (BRI) announced today that results of a study independently conducted by the Department of Surgery at Kurume University Medical Center in Japan have been published. The study, a randomized non-blinded phase 2 trial, compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant therapy with and without Antineoplastons A10/AS2-1 Injections for colorectal metastasis of the liver.
A total of 65 patients, with histologically confirmed metastatic colon adenocarcinoma of the liver, were evaluated. Primary endpoints included cancer-specific survival. Secondary endpoints included relapse-free survival, clinical status and extent of recurrence, salvage surgery rate and toxicity.
BRI believes that the completion of the study represents an important milestone in the development of Antineoplastons and that further efficacy trials of Antineoplastons in colorectal cancer should continue to be pursued.
About Burzynski Research Institute, Inc.
Burzynski Research Institute, Inc. (OTCBB:BZYR) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and development efforts are focused on basic research and phase 3 clinical trials, particularly in the treatment of brain tumors and other forms of cancer.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/burzynski-research-institute-inc-announces-publication-of-phase-2-clinical-study-in-metastatic-colon-adenocarcinoma-of-the-liver-300056848.html
SOURCE Burzynski Research Institute, Inc.
Copyright 2015 PR Newswire
1 Year Burzynski Research Insti... (PK) Chart |
1 Month Burzynski Research Insti... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
